Monday, 13 January 2014

Successful phase 3 trial for ST10 shows promise for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD)

Iron deficiency anaemia is a real problem for many of my patients. Unfortunately patients often struggle with GI side effects caused by conventional ferrous iron salts. Currently we offer such patients intravenous iron in hospital. This is costly to administer, inconvenient for patients and associated with a small but significant risk of anaphylaxis. The exciting AEGIS Phase 3 data suggests that ST10 will provide an effective, safe and more convenient alternative to intravenous iron for this group of patients as demonstrated by ST10 keeping our patients out of the infusion room by correcting and maintaining their haemoglobin in the normal range.

No comments:

Post a comment